Figure 6 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group

Figure 6 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group

<p>Deep learning algorithms can predict event-free and overall survival from H&E histology alone. <b>A,</b> Schematic for training a convolutional neural network for survival. Patients with FN-RMS (<i>n</i> = 264) were partitioned into three groups based on EFS leng...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autor principal:	David Milewski (15050643) (author)
Altres autors:	Hyun Jung (15050646) (author), G. Thomas Brown (15050649) (author), Yanling Liu (15050652) (author), Ben Somerville (15050655) (author), Curtis Lisle (15050658) (author), Marc Ladanyi (15050661) (author), Erin R. Rudzinski (15050664) (author), Hyoyoung Choo-Wosoba (15050667) (author), Donald A. Barkauskas (15050670) (author), Tammy Lo (15050673) (author), David Hall (15050676) (author), Corinne M. Linardic (15050679) (author), Jun S. Wei (14955721) (author), Hsien-Chao Chou (14955718) (author), Stephen X. Skapek (15050682) (author), Rajkumar Venkatramani (15050685) (author), Peter K. Bode (15050688) (author), Seth M. Steinberg (15043179) (author), George Zaki (15050691) (author), Igor B. Kuznetsov (15050694) (author), Douglas S. Hawkins (15050697) (author), Jack F. Shern (14938001) (author), Jack Collins (15050700) (author), Javed Khan (15046967) (author)
Publicat:	2025
Matèries:	Cancer Cancer Detection and Diagnosis Methods and Technology Biomarkers Prognostic biomarkers Computational Methods Artificial intelligence & machine learning Pediatric Cancers Sarcomas Soft-tissue sarcoma
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Figure 1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
per: David Milewski (15050643)
Publicat: (2025)

Figure 2 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
per: David Milewski (15050643)
Publicat: (2025)

Figure 3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
per: David Milewski (15050643)
Publicat: (2025)

Figure 4 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
per: David Milewski (15050643)
Publicat: (2025)

Figure 5 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
per: David Milewski (15050643)
Publicat: (2025)

Supplementary Table S1-S3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
per: David Milewski (15050643)
Publicat: (2025)

Supplementary Tables S1-S5 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era
per: Josephine K. Dermawan (17079555)
Publicat: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
per: Nam Q. Bui (14958210)
Publicat: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
per: Caleb N. Seavey (15056489)
Publicat: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
per: Caleb N. Seavey (15056489)
Publicat: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
per: Srivandana Akshintala (16610490)
Publicat: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
per: Srivandana Akshintala (16610490)
Publicat: (2025)

Supplementary File 1 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary File 2 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary File 3 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary File 4 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary File 5 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary File 6 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary File 7 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary File 8 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
per: Michael P. Ludwig (16721187)
Publicat: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Figure S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
per: Upendra Kumar Soni (15051683)
Publicat: (2025)

Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
per: Upendra Kumar Soni (15051683)
Publicat: (2025)

Figure S3 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
per: Upendra Kumar Soni (15051683)
Publicat: (2025)

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
per: Upendra Kumar Soni (15051683)
Publicat: (2025)

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
per: Upendra Kumar Soni (15051683)
Publicat: (2025)

Figure S6 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
per: Upendra Kumar Soni (15051683)
Publicat: (2025)

Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
per: Upendra Kumar Soni (15051683)
Publicat: (2025)

Supplementary Tables from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
per: Xiangyu Zeng (17314920)
Publicat: (2025)

Video 1_Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report.mp4
per: Shasha Wei (1555588)
Publicat: (2025)

TableS1 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
per: Tingting Liu (15386915)
Publicat: (2025)

TableS2 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
per: Tingting Liu (15386915)
Publicat: (2025)

TableS3 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
per: Tingting Liu (15386915)
Publicat: (2025)

TableS4 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
per: Tingting Liu (15386915)
Publicat: (2025)

TableS5 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
per: Tingting Liu (15386915)
Publicat: (2025)

Supplementary Table S1 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
per: Dongliang Leng (17079663)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lvaal4vn5ae5m8acvvplojbqej